Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Syngenta obtains non-exclusive IP license from Broad Institute for CRISPR-Cas9 genome-editing technology for agriculture applications

Syngenta
Posted on: 02 Nov 17

Syngenta announced today it has attained a non-exclusive IP license from the Broad Institute of MIT and Harvard for CRISPR-Cas9 genome-editing technology for agricultural applications.

CRISPR-Cas9 genome editing technology complements Syngenta’s already robust plant breeding innovation toolbox. Syngenta is applying this technology in multiple crops, including corn, wheat, tomato, rice and sunflower.

“Gaining access to CRISPR-Cas9 technology will allow us to accelerate the rate of innovation in the development of new plant varieties, and bring novel traits into the hands of growers faster, and with greater efficiency,” said Michiel van Lookeren Campagne, global head of seeds research at Syngenta. “Using this advanced technology will help us deliver on the 21st century food production challenges.”

For more information about Syngenta visit www.Syngenta-US.com. Join the conversation online – connect with us at social.SyngentaUS.com.

About Syngenta

Syngenta is a leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Through world class science and innovative crop solutions, our 28,000 people in over 90 countries are working to transform how crops are grown. We are committed to rescuing land from degradation, enhancing biodiversity and revitalizing rural communities. To learn more visit www.syngenta.com and www.goodgrowthplan.com. Follow us on Twitter at www.twitter.com/Syngenta and www.twitter.com/SyngentaUS.

Web Resources:

Know More, Grow More
Syngenta Newsroom
Syngenta U.S.
Thrive

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract there for.

©2017 Syngenta, 9 Davis Dr. Research Triangle Park, NC 27709. The Syngenta logo is a registered trademark of a Syngenta Group Company. All other trademarks are the property of their respective owners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171102005938/en/

Business Wire
www.businesswire.com

Last updated on: 02/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.